An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression.

Colorectal cancers (CRC) with microsatellite instability (MSI) have clinical, pathologic, genetic, and epigenetic features distinct from microsatellite-stable CRC. Examination of epidermal growth factor receptor (EGFR) mRNA and protein expression levels in a panel of colon cancer cell lines identified strong expression of EGFR in multiple cell lines with MSI. Although no relationship between EGFR overexpression and the length of a CA dinucleotide repeat in intron 1 was observed, a variant A13/A14 repeat sequence within the 3'-untranslated region (3'-UTR) of the EGFR gene was identified, which was mutated by either mononucleotide or dinucleotide adenosine deletions in 64% of MSI cell lines and 69% of MSI colon tumors. Using a Tet-Off system, we show that this mutation increases EGFR mRNA stability in colon cancer cells, providing a mechanistic basis for EGFR overexpression in MSI colon cancer cell lines. To determine whether this mutation is a driver or a bystander event in MSI colon cancer, we examined the effect of pharmacologic and molecular inhibition of EGFR in EGFR 3'-UTR mutant MSI cell lines. Cell lines with an EGFR 3'-UTR mutation and that were wild-type (WT) for downstream signaling mediators in the Ras/BRAF and PIK3CA/PTEN pathways were sensitive to EGFR inhibition, whereas those harboring mutations in these signaling mediators were not. Furthermore, in cell lines WT for downstream signaling mediators, those with EGFR 3'-UTR mutations were more sensitive to EGFR inhibition than EGFR 3'-UTR WT cells, suggesting that this mutation provides a growth advantage to this subset of MSI colon tumors.

[1]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[2]  J. Jiricny,et al.  Defective DNA mismatch repair determines a characteristic transcriptional profile in proximal colon cancers. , 2005, Gastroenterology.

[3]  T. Lesuffleur,et al.  Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. , 2008, World journal of gastroenterology.

[4]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[5]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[6]  W. Gerald,et al.  Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study , 2005, Modern Pathology.

[7]  L. Paillard,et al.  AU-rich elements and associated factors: are there unifying principles? , 2006, Nucleic acids research.

[8]  J. Lynch,et al.  Systemic and targeted therapy for advanced colon cancer , 2008, Expert review of gastroenterology & hepatology.

[9]  Rainer Lehtonen,et al.  Background mutation frequency in microsatellite-unstable colorectal cancer. , 2007, Cancer research.

[10]  F. Lee,et al.  Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft , 2005, Cancer Chemotherapy and Pharmacology.

[11]  J. Grandis,et al.  STAT‐mediated EGFR signaling in cancer , 2007, Journal of cellular biochemistry.

[12]  A. Thomson,et al.  Identification of a Novel AU-Rich Element in the 3′ Untranslated Region of Epidermal Growth Factor Receptor mRNA That Is the Target for Regulated RNA-Binding Proteins , 2001, Molecular and Cellular Biology.

[13]  K. Kinzler,et al.  Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.

[14]  M. Orditura,et al.  Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery , 2007, World Journal of Surgery.

[15]  S. Markowitz,et al.  DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[17]  L. Naldini,et al.  Deletion in a (T)8 microsatellite abrogates expression regulation by 3'-UTR. , 2003, Nucleic acids research.

[18]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[19]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Compton,et al.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. , 2007, Gastroenterology.

[21]  M. Leppert,et al.  Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  F. Ciardiello,et al.  Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery , 2006, Annals of Surgical Oncology.

[23]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[24]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[25]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[27]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[28]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[29]  Sanjay Goel,et al.  PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.

[30]  T. Utsunomiya,et al.  Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma , 2005, Clinical Cancer Research.

[31]  Andrew J. Wilson,et al.  Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. , 2003, Cancer research.

[32]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[33]  H. McLeod,et al.  Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.

[34]  S N Thibodeau,et al.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. , 1998, Cancer research.